Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Single domain camel antibodies: current status.

S Muyldermans1

  • 1Vrije Universiteit Brussel, Vlaams Interuniversitair Instituut voor Biotechnologie, Sint Genesius Rode, Belgium. svmuylde@vub.ac.be

Journal of Biotechnology
|August 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combinatorial Design of a Nanobody that Specifically Targets Structured RNAs.

Journal of molecular biology·2018
Same author

Molecular analysis of heavy chain-only antibodies of Camelus bactrianus.

Biochemistry. Biokhimiia·2015
Same author

Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.

Leukemia·2013
Same author

Resolution of an immunodiagnostic dilemma: heavy chain chimeric antibodies for species in which plasmocytomas are unknown.

Molecular immunology·2012
Same author

Chaperonin GroEL a Brucella immunodominant antigen identified using Nanobody and MALDI-TOF-MS technologies.

Veterinary immunology and immunopathology·2012

Camel and llama heavy-chain antibodies provide a unique single-domain antibody fragment, VHH, with excellent antigen-binding properties. These VHH fragments offer advantages over conventional antibodies for various biotechnological applications.

Area of Science:

  • Biotechnology
  • Immunology
  • Protein Engineering

Background:

  • Conventional antibodies rely on paired variable domains (VH-VL) for antigen binding.
  • Early attempts to create single-domain antibody fragments (VH format) faced challenges with solubility and antigen affinity.
  • Camelid heavy-chain antibodies, lacking light chains, naturally utilize single variable domains (VHH) for antigen recognition.

Purpose of the Study:

  • To explore the potential of single-domain antibody fragments derived from camelid heavy-chain antibodies (VHH).
  • To describe methods for accessing and engineering the VHH repertoire for therapeutic and diagnostic applications.

Main Methods:

  • Isolation and characterization of VHH domains from immunized dromedary or llama.
  • Construction and screening of synthetic VHH libraries (camelized human VH, mouse VH, camelid VHH scaffold with randomized CDR3).

Related Experiment Videos

  • Evaluation of recombinant VHH expression, solubility, robustness, and functional properties (e.g., enzyme inhibition).

    • Main Results:

    • Camelid VHH domains exhibit broad antigen-binding repertoires due to enlarged hypervariable regions.
    • Both immune and synthetic VHH libraries yield potent, soluble, and robust antigen-specific binders.
    • Selected VHH demonstrated efficacy as enzyme inhibitors and potential for peptide mimetic design.

    Conclusions:

    • VHH single-domain antibody fragments offer significant advantages over conventional antibody fragments due to their size, solubility, and robustness.
    • VHH are promising for applications including enzyme inhibitors, intrabodies, modular constructs, immuno-adsorbents, and biosensors.